AIPL1

Across TCGA pan-cancer cohorts, AIPL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AIPL1 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AIPL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AIPL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where AIPL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.526	0.825	.001	46	view →
PDAC	DFS	Median	III,IV	0.868	0.491	.018	3	view →
CCRCC	DFS	Median	All	1.000	0.729	.017	3	view →
LSCC	DFS	Tertile	II,III,IV	0.877	0.964	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AIPL1–HNSC (DFS)

Open the HNSC breakdown →